Stealth BioTherapeutics Corp - ADR

NASDAQ:MITO   3:59:50 PM EDT
1.41
-0.03 (-2.08%)
Products

Stealth BioTherapeutics Submits Barth Syndrome New Drug Application To FDA

Published: 08/24/2021 12:33 GMT
Stealth BioTherapeutics Corp - ADR (MITO) - Stealth Biotherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome.
Stealth Biotherapeutics Corp - FDA Has Recommended That Additional Controlled Data Be Generated to Support NDA Review.
Stealth Biotherapeutics Corp - Neither FDA Nor Co Has Identified a Feasible Trial Design Due to Ultra-rare Nature of Disease.
Stealth Biotherapeutics - Believes Data Could Support an NDA Review, Has Accordingly Submitted NDA As Requested by Barth Syndrome Patient Community.